Expenditure on biological drugs for rheumatoid arthritis in the brazilian unified healthsystem between 2012 and 2016.

Abstract

Objective: Analyze the evolution of the budgetary impact of biological medicines for Rheumatoid Arthritis (RA) incorporated into the Unified Health System (SUS) from 2012 to 2016. Methods: The retrospective study, analyzing secondary data in a historical series on the evolution of the budgetary impact of biological medicines incorporated into the SUS for the treatment of rheumatoid arthritis AR. The calculation of Market Share was obtained from the International Classification of Diseases (ICD-10) and Table of Procedures, Medicines, Orthotics, Prosthesis and Special Materials of SUS (SIGTAP). Federal budget funds were drawn from the Federal Integrated Planning and Budget System (Siop), the values of Specialized Component of Pharmaceutical Assistance (CEAF) acquisitions between 2012 to 2016. Results: Biological drugs for AR with the greatest impact on the total expenditure of biologicals for AR under the CEAF were identified, the largest being for adalimumab (R$3.8 billion) ,the lowest for certolizumab pegol (R$ 50.00 million). Aadalimumab had the highest growth rate of users (1,030 patients/year), with growth of 25%, with the lowest expenditure, around R$19.00 million/year and negative growth rate of 14%. IFor infliximab, a drop in consumption was observed (-69 patients/year), and an increasing impact of 4% on CEAF resources. Rituximab showed the lowest demand 745 patients/year, with an expansion of 693%, growth in expenditure by 414%. Conclusions: This study observed the evolution of spending with the acquisition of biological medicines for RA, the significant economic impact for SUS with the expansion of the offer of treatment.